

Alzheimer's Disease (AD)

A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT02353598 GN29632

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This randomized, placebo-controlled, double-blind, parallel-arm study will evaluate the safety and tolerability of at least two dose levels of intravenous (IV) crenezumab in 24-72 participants with mild to moderate Alzheimer disease (AD) (mini-mental state examination [MMSE] 18 to 28 points, inclusive). An optional open-label extension (OLE) will be offered after the completion of initial double-blind stage.

Genentech, Inc.
Sponsor

Phase 1
Phase

NCT02353598 GN29632
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥50 Years & ≤ 90 Years

Healthy Volunteers
No
